Blood test aims to spare lung cancer patients from unnecessary chemotherapy
NCT ID NCT07360743
Summary
This study is testing a new blood test to help doctors choose the best first treatment for advanced lung cancer. It aims to identify patients who can safely receive immunotherapy alone, which can provide long-lasting control, while avoiding the risk of rapid tumor growth that some patients experience. The test measures a 'pro-tumoral inflammation' score to predict who will benefit most from immunotherapy without added chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER (SQUAMOUS OR NON SQUAMOUS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.